Uncategorized
Cybin (NEO: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, recently announced its entry into a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc. for up to CA$20,161,575 (approximately US$15.75 million) in an all-stock transaction. The transaction is subject to the satisfaction or waiver of customary conditions, including receipt of all applicable regulatory and NEO Exchange Inc. approvals. “We are thrilled to join forces with Adelia, as we see this transaction as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s focus on creating novel therapeutics, including novel delivery methods and innovative therapeutic regimens can support our goal of creating therapies that result in faster onset of action, smoother pharmacokinetic profiles, shorter treatment durations, and reduced side effects,” said Cybin CEO Doug Drysdale. “Leveraging Adelia’s expertise across multiple molecules and multiple indications could potentially allow Cybin to extend its reach and capability to address gaps across a larger domain.”
To view the full press release, visit http://ibn.fm/poDlp
About Cybin Inc.
Cybin is a life sciences company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
People work out for different reasons. Some want to keep fit and healthy whiles others have aesthetic in mind; still others may be training for an upcoming competition or event. Doctors recommend working out to maintain good health, advising that we make it part of our daily routines. A good workout plan should factor in the risk of injury and how to avoid it. Injuries only impede your progress. To avoid this, here are some ways you can avoid injuries whe working out.
Stretch and do warm-up exercises before you begin.
Taking a few minutes to warm up helps your muscles loosen up before you commence your workout. Stiff muscles are susceptible to injury. You can choose from various warm-up exercises. However, it’s recommended that you do warm-up exercises that will help loosen the muscles in the part of the body that your workout is focused on. Some common warm-up exercises include leg and arm lifts, pushups and walking.
Start your workout slow
If you haven’t exercised in a while, you should start with slow workouts. Muscles need time to get used to the stress that comes with working out. So you should avoid getting into working out again too fast with intense workouts. Some soreness in your muscles after exercise is completely normal, but be aware of the danger of overworking your muscles when working out. If that’s the case, you will need to slow down.
Work on being more flexible
Being more physically flexible is good for your body. Improving your body’s flexibility also prevents you from injuring your muscles when working out. Additionally, flexibility helps your muscles withstand more physical stress. Activities such as dynamic stretches and yoga will help steer clear of muscle underdevelopment and weakness. Muscles that are underdeveloped or weak are prone to tears and pulls. Enhancing your flexibility will make your muscles stronger.
Give yourself time to recover
When working out, you should ensure that your body has time to rest. Some people believe that rest time in between workouts only impedes your progress, but that isn’t true. Taking time to let your body recover helps ensure that you do not overwork your body. When working out, your muscles are engaged. Recovery time gives your body time to repair. Working out every day with no days off in between workouts will result in your muscles breaking down and being more prone to injury.
Lots of firms are busy at work ensuring that people enjoy better health. For example, CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is notable among biotech companies because of its focus on searching for treatments targeting cancers that attack the brain impact the central nervous system.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- CNS Pharmaceuticals featured in audio broadcast distributed to thousands of syndication points.
- Berubicin IND accepted for review by FDA
- Phase 1 trial showed 44% of patients experiencing clinical benefit of stable disease or better
- Adult Phase 2 trials to commence in Q1 2021
The IND filing for brain cancer drug Berubicin has been accepted for review by the U.S. Food and Drug Administration (“FDA”), reports CNS Pharmaceuticals (NASDAQ: CNSP), the company now responsible for the drugs’ development. That news was featured in a recent syndicated NetworkNewsAudio (“NNA”) broadcast, which covered CNS Pharmaceuticals’ recent submission of an Investigational New Drug (“IND”) application to the FDA for Berubicin. The broadcast also detailed the company’s plans to commence adult Phase 2 trials of the drug during the first quarter of 2021.
Since review of the IND application has not been completed, it may seem a little strange that CNSP is already looking ahead to Phase 2 clinical trials. However, Berubicin has already been the subject of Phase 1 trials, which are focused on finding the safest effective dose of a drug. In 2006, Reata Pharmaceuticals, a clinical-stage biopharmaceutical company conducted clinical trials that have had quite encouraging results.
Fortuitously, 11 of the 25 cancer patients who were treated with Berubicin and were available for evaluation in those initial clinical trials “experienced a statistically significant improvement in progression-free survival” (https://ibn.fm/OgkZB). Moreover, “one patient experienced a durable complete response, which is defined by the National Cancer Institute as the disappearance of all signs of cancer in response to treatment.” This means that that patient has suffered no recurrence and has remained cancer free for more than 13 years. Two other patients saw reductions in tumor size of up to 80%.
Berubicin has been developed to treat glioblastoma multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable. The drug is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs. Anthracyclines are also effective against more types of cancer than any other class of chemotherapeutic agents. They are designed to utilize natural processes to induce deoxyribonucleic acid (“DNA”) damage in targeted cancer cells by interfering with the action of topoisomerase II, a critical enzyme enabling cell proliferation. In effect, Berubicin prevents cancerous cells from replicating.
The Phase 2 clinical trials will be conducted in conjunction with WPD Pharmaceuticals Inc. Additionally, there are plans afoot for WPD Pharmaceuticals to commence a first-ever Phase 1 trial with children in the near future. This pediatric trial will be conducted at Children’s Memorial Health Institute, the largest pediatric hospital in Poland.
CNSP is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. In June 2020, the company hired U.S.-based Pharmaceutics International Inc. (“Pii”) and Italian BSP Pharmaceuticals S.p.A. (“BSP”) to handle production of the drug. Synthesis of the Berubicin Active Pharmaceutical Ingredient (“API”) had already been completed, and the API has been delivered to the two manufacturing entities; both have now prepared an injectable form of Berubicin to be used in the clinical trials.
With the production process fully underway, the company is a step closer to getting its IND approved by the FDA. With this dual-track approach to manufacturing, the company reduces the risk of failing to meet its clinical timeline. Moreover, situating production in Europe as well as the United States provides localized availability of Berubicin for the upcoming Phase 1 pediatric and Phase 2 adult studies in Poland and the U.S. Phase 2 trials.
Glioblastoma is one of the most aggressive primary brain cancers in adults, with approximately 13,000 new patients diagnosed each year in the U.S.—the highest diagnosis rate of all malignant brain tumors. An effective way of fighting this pernicious affliction is sorely needed.
For more information, visit the company’s website at www.CNSPharma.com
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
It may be conceivable that everyone has a phobia; some are small while others can be crippling. Remember Ron Weasley and his phobia of spiders? While some people are only slightly fazed by their phobias, which are defined as irrational fears, others are significantly impacted by them, going as far as to avoid doing certain things or going to specific places because of them.
According to the National Institute of Mental Health, nearly 19 million individuals in the United States have a phobia, making phobias a common mental disorder in the nation. Some evidence indicates that the use of marijuana could benefit those struggling with these intense fears.
Evidence gathered in the last six years shows that cannabis compounds, or cannabis in general, may be used to help individuals with specific phobias. A study conducted by the University of Michigan discovered that THC, which is a cannabis compound, may alleviate the anxiety of patients with phobia. In the study, which was reported in the “Neuropsychology” journal, researchers cited the discovery that THC helped some patients with phobias to not only work through their fears but also overcome them.
The study involved nearly 30 participants and utilized a skin conductance response recording and a simultaneous Pavlovian fear extinction paradigm during the study. The researchers dosed patients using dronabinol, which is a synthetic version of THC. They noted that over time individuals who were under the influence of THC exhibited less fear.
Study results provided evidence suggesting that extinction learning of phobias through pharmacological enhancement was achievable in humans through the use of cannabinoid system modulators. The authors of the study concluded that this called for more clinical research and testing to be conducted.
A separate 2017 study demonstrated that CBD, another cannabis compound may possess therapeutic benefits that help deal with certain phobias. The study, published in the “Frontiers of Pharmacology,” was led by University of Birmingham’s Chenchen Song. The study used rats as tests subjects and administered 10mg CBD injections to the rats.
Researchers observed that these injections decreased the fear memory in the rodents. While rats aren’t privy to human fears such as flying or heights, Song notes that the marijuana component they administered made the rodents less afraid of being eaten alive by predators. CBD has also proven effective in helping treat PTSD.
From the above, it is feasible that individuals who have phobias may use medical cannabis to help alleviate their fears. Phobias are currently managed by using tranquilizers and antidepressants, which may do more harm than good.
Many cannabis-related entities have opted to focus on lifestyle products. For example, The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) has become famous for its trace mineral-rich alkaline water as well as its topicals and edibles infused with cannabidiol.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
NEW YORK, Dec. 09, 2020 — via InvestorWire — The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.
To view the full publication, “National Brands Vie for CBD Dominance,” please visit: https://nnw.fm/WYoJD
On election day this year, four more states voted to legalize the recreational use of cannabis, bringing the total of states that now allow recreational cannabis use to 15. This growing acceptance of cannabis, and more specifically CBD, which is now legal in all 50 states, has sparked an explosion of new CBD-infused products and brands within the consumer packaged goods (CPG) space. Estimates about how large the legalized cannabis market may grow vary widely, but a Lido Consulting report notes that the total addressable cannabis market (TAM) could potentially hit $1 trillion in global economic impact by 2027.
Seeing almost unlimited potential, companies are rushing to take advantage of the massive opportunity. Continuing its aggressive growth strategy, The Alkaline Water Company Inc. (NASDAQ: WTER)(CSE: WTER) entered the CBD space with the launch of its A88CBD(TM) brand. Already nationally recognized for its premium bottled water and flavor-infused water, Alkaline Water now features a full line of CBD-infused and topical products. After posting record sales earlier this year, this strategic push into the lucrative CBD market could propel the company to new records.
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com .
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://nnw.fm/WTER
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.
NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
Loop Insights (TSXV: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick-and-mortar space, today announced its entry into a memorandum of understanding (“MOU”) with SimpliFlying, the world’s leading aviation marketing consulting firm, to support specific near-term opportunities with world renown resorts, national tourism boards, major airlines, airports, cruise ships, and ports. On Oct. 19, 2020, Loop and Empower Clinics (CSE: CBDT) (OTC: EPWCF) (FRA: 8EC) announced a partnership that created the first-ever COVID-19 “Travel Bubble,” combining each company’s respective expertise in venue tracing and testing, each of which has made significant technological advancements and milestones in the interim. “This partnership is a very important and powerful next step to accelerate Loop’s potential growth. With the company’s recent launch of its first live venue events, with the whole world watching, including world-renown venues and hospitality companies, Loop hit it out of the park and provided the world with the empirical data necessary to demonstrate our bubble solution is nothing short of world-class,” said Loop Insights CEO Rob Anson. “By adding the direct integration with Empower’s diverse testing capabilities and SimpliFlying’s network of large-scale customer projects, we have now commenced significant discussions surrounding travel bubble opportunities with some of North America’s largest airlines, resort operators, venues, and hospitality groups globally. We anticipate this new revenue stream may be significant for the company as we progress these opportunities in 2021.”
To view the full press release, visit https://ibn.fm/1alw7
About Loop Insights Inc.
Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network. For more information, visit the company’s website at www.LoopInsights.ai.
NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at http://ibn.fm/RACMF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- SRAX to host 13th Annual LD Micro Main Event on December 14-15, 2020 via its SRAX Virtual Events SaaS platform
- Conference will feature over 250 company presentations, interviews include Shaquille O’Neal and 2020 presidential candidate Brock Pierce
- 2 million+ small-cap investors invited from SRAX’s active investor base
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, will be hosting the 13th Annual LD Micro Main Event on December 14-15, 2020 via its Sequire Virtual Events SaaS platform. Over 250 companies are scheduled to present to a potential audience of over 2 million invited guests. Attendees will have exclusive access to interviews with Shaquille O’Neal and 2020 presidential candidate Brock Pierce along with other influential panelists across the small-cap space.
Since being acquired by SRAX, LD Micro – already a leader in small- and micro-cap conferences – has gained access to the largest active base of micro-cap investors in the world at over 2 million and counting. Since its inception in 2006, LD Micro has grown from a newsletter into a prominent portal that provides exclusive intraday information covering North American stocks with market capitalizations between $50 million and $300 million. The LD Micro Main event this year is set to be one of the company’s most ambitious endeavors in its history, set to bring together millions of potential investors with companies in the flourishing micro-cap space.
“I think the Main Event will be the first virtual conference this year that is engaging instead of repetitive,” said LD Micro Founder and CEO Chris Lahiji (https://ibn.fm/bAOws). “There have been too many 20-minute PowerPoints, and investors have lost the desire to watch one more of the same thing. We intend to showcase something different.”
Besides its all-new presentation format, the conference will be presented on Sequire, SRAX’s SaaS platform that leverages data analytics for public companies. Tailored to the investment industry, Sequire helps public companies unlock valuable data and insights that can be used to create and activate marketing campaigns in order to attract new investors and engage existing shareholders.
“With the launch of this virtual conference, we are one step closer to our mission of creating the most comprehensive platform for issuers,” said SRAX Founder and CEO Christopher Miglino. “We believe this conference will be a success for both the investors and the issuers in the Sequire community, and we look forward to the expansion of the LD Micro audience.”
Investor relations in recent years have undergone a rapid transformation with the advent of data-based platforms that allow public companies to track their investors’ behaviors and trends. The movement is projected to continue at a rapid pace, positioning SRAX favorably in the investor relations industry, set to radically transform from innovations in the collection and application of investor data.
For more information, visit the company’s website at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, REQORSA(TM) (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.
Genprex will present at the Benzinga Global Small Cap Conference on December 8, 2020 at 2:30 p.m. EST. Genprex’s President and Chief Executive Officer, Rodney Varner, will virtually deliver a company overview, including recent progress made on its upcoming Acclaim-1 clinical trial, to participating investors.
For more information, visit the company’s website at www.genprex.com.
For further details on Benzinga’s Global Small Cap Conference and other events, visit https://www.benzinga.com/events/small-cap/
About InvestorBrandNetwork’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, covers dozens of investor conferences and online events as part of its ongoing service to the investment community. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of each featured session.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its many event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
Scientists at the Georgia State University Institute for Biomedical Sciences have found that the MK-4482/EIDD-2801 antiviral drug, which was developed to treat the SARS-CoV-2 infection, completely stops transmission of the virus in 24 hours.
The researchers, led by distinguished Georgia State University professor Dr. Richard Plemper, initially discovered that the drug was strong against influenza viruses. Plemper explains that this was the first test for a drug that is orally available and that can stop the transmission of SARS-CoV-2. He adds that MK-4482/EIDD-2801 may be a game-changer.
Stopping the transmission of the SARS-CoV-2 virus on a wide scale until vaccination is available to the masses is key, as it allows authorities to manage the coronavirus while reducing the catastrophic consequences the pandemic may create.
As the drug can be ingested orally, treatment can commence early for the following benefits: to quickly avert any local outbreaks; to cut down the infectious phase, which will in turn relieve both the socioeconomic and emotional toll of patient isolation; and to slow down the progress of the deadly disease.
Plemper also explains that in the early stages of the study, the researchers noted that MK-4482/EIDD-2801 can be used to fight against many respiratory RNA viruses, adding that when used by mouth to treat infected animals, the drug decreased the number of viral particles that were shed, which decreased transmission. These attributes made the drug a strong coronavirus pharmacologic control candidate.
Plemper’s team reused the drug on a ferret model to observe the impact the drug had on stopping the virus from spreading. The study, which was published in “Nature Microbiology,” documents these findings in detail. The researchers initiated the MK-4482/EIDD-2801 treatment after the ferrets began to discharge the virus through their noses after they had been infected with the SARS-CoV-2 virus.
The co-lead author of the study, Dr. Robert Cox, states that the researchers believed ferrets to be a suitable transmission model because, while they mostly don’t develop the SARS-CoV-2 disease, they readily spread it. This bears a resemblance to how the virus is spread in young adults.
Another co-lead author of the study, Josef Wolf, a Plemper lab doctoral student, observed that no ferrets were infected with the virus when the researchers joined ferrets that were infected with the virus but had been treated with ferrets that did not have the virus. Translated to humans, this means that patients who have the coronavirus and are treated using this drug could become non-infectious within the first 24 hours after their treatment commenced. The drug is currently in its phase 2 and 3 of advanced clinical trials.
The SARS-CoV-2 virus isn’t the only health threat that we are currently confronted by. Cancer is another growing problem, which is keeping lots of firms hard at work. For instance, Predictive Oncology (NASDAQ: POAI) has devoted all its energies towards developing customized cancer treatments by tapping the powers of data analytics and AI.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for Dec. 1, 2020, which will be reconvened to 3 p.m. CST on Dec. 30, 2020. According to the update, POAI’s board of directors and management urge all shareholders to vote in favor of the proposals being considered at the special meeting, primarily because the reincorporation in Nevada will eliminate its obligation to pay the injurious annual Delaware franchise tax, currently equal to approximately $170,000 per year. Predictive Oncology can save approximately $158,000 annually in state taxes by reincorporating in Nevada.
To view the full press release, visit: https://ibn.fm/wMinE
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a developer of innovative solutions for the worldwide life science and other industries, recently reported its third-quarter financial results and provided a business update, which included initial expectations for 2021 (https://ibn.fm/8PNFi). Among the updates, the Q3 2020 Form 10-Q financial report outlines measurable progress in three important areas: key operational and technical projects; revenue increases in the company’s products and services offerings; and important structuring improvements in the reduction of arduous, variable-rate convertible debt. A recent article discussing this reads, “Providing other updates and plans for 2021, the Form 10-Q report also mentioned that Pressure BioSciences is on track to launch its innovative BaroShear K45 Nanoemulsification System by mid-2021. Purchase orders for the 12 BaroShear K45 systems the company intends to manufacture in early 2021 have already been received ahead of the planned mid-2021 commercial release. This novel and proprietary system, based on the company’s Ultra Shear Technology(TM) (‘UST’) patented platform, is designed to revolutionize the processing of immiscible liquid into water-soluble nanoemulsions.”
To view the full article, visit https://ibn.fm/rmySv
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life science and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in a Phase I clinical trial. As a result of the trial, 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS recently submitted an Investigational New Drug (“IND”) application with the FDA, and, pending approval, it intends to commence a pivotal Phase II clinical trial in the U.S. “I have done all kinds of different things in my career, been in the health care industry for a long time. This is the most exciting thing that I’ve done,” Climaco said in the interview. “This company and our lead product have the potential to really change the landscape and the game in an area of oncology that hasn’t seen a lot of hope for a very long time in glioblastoma.”
To view the full press release, visit http://ibn.fm/Swa22
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and health care platform, today announced the launch of Trxade Prime, a revolutionary service offered by the company’s Integra Pharma Solutions subsidiary. According to the update, Trxade Prime solves a historic problem for independent pharmacies suffering from an already complex prescription distribution process. The solution allows Trxade platform independent pharmacy members to process, consolidate and ship purchase orders placed directly with Trxade Suppliers via the Trxade Prime service. “The mission of Trxade, from its inception, has been to empower and encourage growth within the independent pharmacy community,” said Trxade Group CEO and Founder Suren Ajjarapu. “The development of Trxade Prime was the result of feedback from our significant pharmacy member base on ways to enhance purchasing efficiencies and cost savings. The overwhelming feedback Trxade received includes the difficulties pharmacies face meeting multiple supplier requirements on order minimums, individual invoicing with vastly varied payment terms and the lack of consolidated information with regard to tracking multiple orders with differing delivery dates, times and shipping costs.”
To view the full press release, visit http://ibn.fm/lvc9Y
About Trxade Group Inc.
Headquartered in Tampa, Florida, Trxade Group is an integrated drug procurement, delivery and health care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health care services affordable and accessible. Founded in 2010, Trxade Group is comprised of three synergistic operating platforms: (1) the Trxade B2B trading platform with around 11,800 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; and (3) the Bonum Health platform offering affordable telehealth services. For additional information, please visit www.Trxade.com and www.BonumHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Delivery services have proliferated during the coronavirus pandemic as a result of the many restrictions imposed in a bid to contain the deadly virus. Marijuana delivery has not been left behind, with the substance becoming more accessible in many parts of the country. However, because this service is a little difficult to maneuver and new to the industry, there are a few things to consider when choosing a delivery service that works for you, while keeping laws on marijuana delivery in mind.
Determine if they accept debit/credit cards
While some states may limit marijuana sales to cash, delivery services where medical marijuana delivery is allowed may accept debit and credit cards. Additionally, you should inquire on the other payment methods they accept.
Check if the delivery service is compliant
All legal medical marijuana delivery services are required to follow local and state marijuana laws. If you plan on using any medical marijuana delivery service, you should ensure that the delivery service you will be using has its legal documentation in order. This will keep you from running into any legal trouble while also ensuring that you get your marijuana products from a creditable source.
To do this, you should look for the medical marijuana license for the delivery company. This is usually displayed in email communications and on websites.
See if the company’s services are local
Legal medical marijuana delivery services are mostly linked to local businesses, which either cater to a certain location or have a reputable name in the area. If a service is not local, they may omit that information, thereby providing a clue about their location.
Ask if your purchase is tax inclusive
Medical cannabis products are taxed, just like any other consumer product. If your delivery service doesn’t tax their products, you should tread carefully or terminate the use of their services, as they may not be complying with local restrictions and regulations.
You should also ask whether you require a medical cannabis card to place your order. This will allow you to seek delivery services that do, in fact, cater to medical cannabis cardholders, thus saving you time.
Identify the delivery time frame
You’ll want to find a medical marijuana delivery service that is convenient, provides you with a specific delivery time frame, and delivers your order on time. Additionally, the service should update you on the timeline and route of your order delivery and provide you with approximate delivery times. Beware of any service that delivers orders unusually late in the evening/night.
Excluding medicinal marijuana products, many firms are making products that are proving to be popular among consumers. One such entity is The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER). This Arizona-based company focuses on producing alkaline drinking water containing numerous trace minerals; WTER also recently added a line of CBD edibles and topicals.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
NetworkNewsWire Editorial Coverage: On election day this year, four more states voted to legalize the recreational use of cannabis, bringing the total of states that now allow recreational cannabis use to 15. This growing acceptance of cannabis, and more specifically CBD, which is now legal in all 50 states, has sparked an explosion of new CBD-infused products and brands within the consumer packaged goods (“CPG”) space. Estimates about how large the legalized cannabis market may grow vary widely, but a Lido Consulting report notes that the total addressable cannabis market (“TAM”) could potentially hit $1 trillion in global economic impact by 2027. Seeing almost unlimited potential, companies are rushing to take advantage of the massive opportunity. Continuing its aggressive growth strategy, The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) (Profile) entered the CBD space with the launch of its A88CBD(TM) brand. Already nationally recognized for its premium bottled water and flavor-infused water, Alkaline Water now features a full line of CBD-infused and topical products. After posting record sales earlier this year, this strategic push into the lucrative CBD market could propel the company to new records. Also quick to see the opportunity, Constellation Brands Inc. (NYSE: STZ) recently exercised warrants to purchase additional shares of Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED), increasing its stake in the Ontario cannabis producer to more than 38%. In a nod to the value of having CPG expertise, Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) has appointed Miguel Martin, an international CPG executive, as its chief commercial officer. And Charlotte’s Web Holdings Inc. (OTC: CWBHF) (TSX: CWEB) has announced a collaboration between its CW Labs science division and the University at Buffalo’s Center for Integrated Global Biomedical Sciences to advance hemp cannabinoid science through a research program that provides a better understanding of the therapeutic uses and safety of cannabinoids.
- Growing acceptance of cannabis, specifically CBD, has sparked explosion of new CBD-infused products, brands within the consumer packaged goods (CPG) space.
- WTER’s A88CBD product line meets stringent requirements as CBD becomes more mainstream.
- Well-financed suitors may well be interested in The Alkaline Water Company given its unique niche strength, appeal.
A Massive Consumer Base
“Pause to consider,” the Lido Consulting article observed, “a $1 trillion market in eight years while currently there is not a single company in the space that generates anywhere close to $500 million in revenue. That fragmentation, and the wholly unique phenomenon that a black market with an existing — and massive — consumer and patient base is transitioning to a regulated market, is what makes cannabis such a compelling opportunity.”
That demand has only increased in the past year, with the COVID-19 epidemic fueling online sales. In fact, one study reported that every dollar spent on email marketing in the CBD industry resulted in almost $40 in revenue. And research by the Brightfield Group shows that roughly one-third of the CBD consumers surveyed indicated they are planning to buy from online retailers rather than in-store during the pandemic, while nearly 50 percent say they will stock up on supplies if they believe there is going to be a shortage.
The industry seems primed for a leading company to offer a comprehensive line of CBD-infused and topical products — and emerge as a trusted brand. Who better to step into the spotlight than an innovative company that has already firmly established its ability to quickly identify and deliver on consumer needs and market opportunities?
CBD Attracts New Wave of Entrants
Already a well-respected national beverage brand, The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) is committed to building a similar reputation in the CBD sector. With those high standards in mind, WTER ensures all its A88CBD products are formulated in GFM facilities; use the highest-quality, lab-tested CBD from a trusted source; and follow rigorous quality control measures to establish consistency.
These stringent requirements are essential as CBD becomes more mainstream, attracting a new wave of entrants. Large national retailers are actively looking to add quality CBD products to their shelves, but these distributors have stringent requirements. Smaller cannabis producers and new brands with limited resources lack the resources to provide such high-quality products. However, their weakness is The Alkaline Water Company’s strength.
As a trusted brand, WTER and its best-in-class A88CBD brand offer precisely what retailers are looking for: superior quality topicals, oils, capsules, tinctures and gummies.
Capturing Share in Large, Growing Markets
The Alkaline Water Company is deeply committed to its A88CBD line, launching five category-leading items during Q2 FY 2021. “These products, which include our delicious lemon-lime CBD water, vegan gummies, zero-calorie powder packs, all-natural bath bombs and cruelty-free deep relief cream, complement our existing product lineup,” said WTER president and CEO Richard A. Wright. “Our robust product lineup effectively positions us to capture share in the estimated $20 billion-plus, hemp-derived consumer products market.”
Intent on capturing as much of the growing market as possible, WTER is strengthening both its online and in-store presence. A88CBD products are currently available on the company’s direct-to-consumer e-commerce site at www.A88CBD.com and in approximately 400 retail locations, including Elevated Wellness CBD, CBD Emporium, Alchemist Kitchen, Pure CBD, and select Vitamin Plus locations; the products are also available online at Amazon, CBD.co, healwithnature.com and DirectCBDOnline.com. Having both a vibrant online presence and robust retail locations is essential for companies committed to increasing sales in the CBD space. With that in mind, Wright also noted that the company is looking to continue to expand its online presence through unique digital marketing strategies and leverage its existing brick-and-mortar footprint for its A88CBD portfolio of products.
“We are in active discussions with over 9,000 retail locations to take on our products over the coming 90 days,” he said during the Q2 financial webcast. “With an in-demand portfolio of offerings, a strong partner network, and an established retail base, we are taking aggressive actions to capture share in the large and growing retail trades we currently serve and greenfield opportunities in the CBD and hospitality and foodservice arena. Additionally, our e-commerce sites continue to exceed our expectations and provide another growth area driven by shifting consumer behaviors. We also expect the multi-year health and wellness trend to accelerate coming out of the COVID pandemic and anticipate our lifestyle brands to benefit due to our sales and marketing efforts made this year.”
A Strong Candidate Fills Unique Niche
A88CBD is only a piece of The Alkaline Water Company’s strategic business approach. The company’s flagship product, Alkaline88(R), continues its strong performance in the beverage world, contributing to the company’s record sales reported in October. “Our family of brands — Alkaline88, A88 Infused and A88CBD Infused — include a growing portfolio of products that are in demand and resonate with consumers,” Wright said.
A recent Proactive Investor article noted that “well-financed suitors may well be interested in the Alkaline Water Company given its unique niche. After all, a Neilson report ranked Alkaline88 as ‘one of the fastest growing’ value-added waters in 2019. It also noted that [the company] has built a ‘national retail footprint’ and extended its lifestyle brands into other consumer packaged goods categories.”
WTER’s consistency and commitment to quality, along with its unique variable-cost business model and growing portfolio, certainly bode well for the company, making it a strong candidate for a savvy beverage or cannabis brand looking to strengthen its position in the growing sectors.
Evaluating, Seizing the Opportunities
With a trillion-dollar industry projection providing incentive, WTER isn’t the only CBD company to strategically evaluate — and seize — the opportunities.
Back in 2017, Constellation Brands Inc. (NYSE: STZ), a leading beverage alcohol company, signed an agreement to acquire a 9.9% minority stake in Canada-based Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED). The investment was consistent with Constellation Brands’ long-term strategy to identify, meet and stay ahead of evolving consumer trends and market dynamics, while maintaining focus on its core total beverage alcohol business. Constellation’s move earlier this year to significant increase that interest signifies the company’s recognition of possibilities within the industry.
“While global legalization of cannabis is still in its infancy, we continue to believe the long-term opportunity in this evolving market is substantial,” said Constellation Brands president and CEO Bill Newlands. “Canopy is best positioned to win in the emerging cannabis space.”
Aurora Cannabis Inc.’s (NYSE: ACB) (TSX: ACB) new chief commercial officer has deep, diverse experience in consumer packaged goods, highly regulated industries and the U.S. cannabinoid industry. “Miguel is a highly experienced executive with an exceptional track record of performance in a number of consumer products categories,” said Aurora executive chairman Michael Singer. “The Aurora Board and I firmly believe that under Miguel’s leadership, Aurora’s strategic direction going forward will be characterized by leading market performance, sustainable growth, profitability and value creation for shareholders.”
Charlotte’s Web Holdings Inc.’s (OTC: CWBHF) (TSX: CWEB) new scientific initiative with the University at Buffalo’s Center for Integrated Global Biomedical Sciences includes collaboration on a global program to advance cannabinoid sciences implementation research and safety for both supplement and biomedical use of cannabinoids. The objective of the partnership is to identify optimal approaches to advance the safe use of cannabinoid-containing products and identify the gaps in current knowledge.
This growing acceptance of cannabis, and specifically CBD, isn’t likely to slow and has sparked the explosion of new CBD-infused products and brands within the consumer-packaged goods (“CPG”) space. Industry leaders in this explosive growth market are positioned for exponential growth.
For more information about The Alkaline Water Company, please visit The Alkaline Water Company.
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a financial news and content distribution company, one of 40+ brands within the InvestorBrandNetwork (“IBN”), that provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience comprising investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Through its subsidiary Soluble Biotech, the company delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations. A recent article discussing this reads, “HSC Technology is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations (https://ibn.fm/QPo4W). The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination of additives and excipients, resulting in increased solubility and physical stability of proteins. And while the technology produces unparalleled optimization results, it provides other benefits as well.”
To view the full article, visit: https://ibn.fm/5qPG1
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has reached a significant milestone. The company successfully completed the technology transfer of its manufacturing process for the production of its lead candidate for immunogene therapy, REQORSA(TM). The transfer was made from the major cancer research institution where it had previously been manufactured to experienced, commercial contract development and manufacturing organizations (“CDMOs”). This step marks the first time REQORSA has been manufactured outside of the research institution where it was discovered and at commercial scale in a current Good Manufacturing Practices (“cGMP”)-compliant facility. According to the company, the move will provide production and process improvements that will result in a reliable, scalable, reproducible and stable drug product suitable for storage, shipment and patient use. “The successful completion of our manufacturing technology transfer represents a major milestone for Genprex,” said Genprex president and CEO Rodney Varner in the press release. “We are delighted to collaborate with leading, global CDMOs that have enabled us to complete the successful engineering batch. We are now focused on the completion of commercial scale production of REQORSA, for use in our two upcoming clinical trials. At the same time, our clinical group is engaging with clinical trial sites who will recruit and treat patients related to our clinical trials.”
To view the full press release, visit http://ibn.fm/BVPes
About Genprex Inc.
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Energy Fuels Inc (NYSE American:UUUU) traded at a new 52-week high today of $2.99. This new high was reached on above average trading volume as 4 million shares traded hands, while the average 30-day volume is approximately 2.2 million shares.
Energy Fuels is the largest uranium producer in the U.S. and holds more production capacity and uranium resources than any other U.S. producer. The Company also produces vanadium.
Energy Fuels Inc has overhead space with shares priced $2.60, or 18.7% below the average consensus analyst price target of $3.20.
In the past 52 weeks, Energy Fuels Inc share prices are bracketed by a low of $0.78 and a high of $2.99 and is now at $2.60, 234% above that low price.
Receive IBN`s Technical Indicator Alerts
To stay connected with our complimentary IBN alerts, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading producer of uranium in the United States, recently announced a corporate update and financial results for the quarter ended Sept. 30, 2020 (https://ibn.fm/CEDLQ). In addition to being debt free, Energy Fuels had working capital of $44.7 million at the end of Q3 2020, which is a 17% increase over Q2 2020. An article discussing Energy Fuels’ ability to achieve a debt-free status quotes the company’s president and CEO Mark S. Chalmers, who stated, “While many uranium and other natural resource companies have significant debt burdens, Energy Fuels is proud to announce that today we became debt free. Being debt free distinguishes Energy Fuels not only from many of our peers in the uranium and natural resource sectors but also from many public companies in general. Having no debt reduces costs and allows Energy Fuels to better weather market volatility. Coupled with our strong working capital position, this also provides us with a ‘clean slate’ from which to increase uranium production when warranted and to launch the exciting rare earth element initiative we are pursuing. We have a number of opportunities in front of us right now, any one of which could result in significant cash flows for the company.”
To view the full article, visit https://ibn.fm/rebL4
About Energy Fuels Inc.
Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and is evaluating the potential to recover rare earth elements at its White Mesa Mill. Its corporate offices are in Lakewood, Colorado near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming, and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol “UUUU,” and the Company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol “EFR.” For more information, visit the company’s website at www.EnergyFuels.com.
NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
Creatd (NASDAQ: CRTD), the parent company of Vocal, a proprietary creator platform, today announced that it has converted its 10,000th freemium creator to a paid Vocal+ subscriber, a milestone achieved several weeks ahead of management’s year-end target. According to the update, Creatd has expanded its Vocal+ premium subscriber base by over 33% in the last three weeks alone, while experiencing record low subscriber acquisition costs. “With the Vocal platform having crossed 10,000 Vocal+ paid subscribers, coupled with a more focused, more accountable sales strategy, I am enthusiastic about our ability to increase our average contract price as well as the number of clients who will engage our services in 2021,” said Laurie Weisberg, Creatd’s chief operating officer.
To view the full press release, visit http://ibn.fm/BPBVg
About Creatd Inc.
Creatd empowers creators, brands and entrepreneurs through technology and partnership. Its flagship technology platform is Vocal; Vocal provides creators of all shapes and sizes, from bloggers to podcasters, and more, with best-in-class storytelling tools, safe and curated communities, and the opportunity to monetize their content. With 34 owned and operated communities, Vocal enables creators to connect to their ideal audiences and to partner with the brands that want to reach those audiences. For more information about Creatd and its Vocal platform, visit www.Creatd.com and www.Vocal.media.
NOTE TO INVESTORS: The latest news and updates relating to CRTD are available in the company’s newsroom at http://ibn.fm/CRTD
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat the deadly brain cancer Glioblastoma Multiforme (“GBM”). The company recently announced that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review and discussed a novel clinical design for its upcoming Phase 2 U.S. trial in a webinar open to the public. “I would like to remind everyone that this upcoming Phase 2 trial will build on the success of the Phase 1 trial of Berubicin in which the clinical benefit response was 44%, including one patient … who had a durable complete response and is still alive and cancer-free today, 14 years after treatment with Berubicin, and another two patients with partial responses, who had reductions of greater than 25% in the size of their tumors,” CNS Pharmaceuticals CEO John Climaco told the webinar audience.
To view the full article, visit: https://ibn.fm/UGq02
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
A landmark study has found that cannabidiol (CBD) doesn’t trigger driver impairment when taken in small doses while the impairment caused by THC fizzles out in just a matter of hours.
The researchers based at Sydney University in Australia concluded that when drivers consume small amounts of THC, which trigger intoxication similar to that experienced by an individual who takes alcohol resulting in a 0.05 percent blood alcohol level, the impairment of their driving competence faded within four hours after consumed the dose of marijuana.
This study comes at a time when many people are concerned about the likely effects of the increasing legalization of cannabis, either for medicinal or recreational purposes.
For example, opponents of legalization keep insisting that cases of cannabis-impaired driving will increase, but the lack of concrete evidence to that effect waters down their arguments.
Similarly, medical cannabis patients constantly worry that they could be prosecuted for impaired driving days after they consumed their medicine if metabolites are detected in their blood during a roadside test.
The Sydney research helps to reassure all concerned, especially those users the substance, that they are unlikely to endanger anyone on the road as long as wait several hours after consuming the small dose of THC-rich medical marijuana.
To quantify the impact of cannabinoids upon drivers, the scientists divided the study participants into four groups. Each group was then requested to vaporize a different cannabis blend. One blend mainly had THC, another contained mainly cannabidiol, a third product was composed of a mix of those two cannabinoids, while the fourth product was a placebo with hardly any cannabinoids.
For all blends having the two main cannabinoids being studied, the concentration was capped at 13.75 mg.
All participants then had to drive (twice) 100 km on a highway in the Netherlands. The first drive was initiated 40 minutes after the participants had vaporized the blend, while the second round of driving took place four hours later. Each driver had a licensed instructor observing them throughout the trip.
A barrage of data was collected from the drivers in a laboratory. For example, the concentration of cannabinoids in their blood was measured, as was their cognitive performance. During the driving test, each participant was observed to see the extent to which their vehicle drifted outside their specific assigned lane. This is a common metric used to track impaired driving.
The study indicates that for the drivers who had taken the small dose of CBD, no signs of impairment were detected during either of the driving tests. However, individuals who consumed the product containing THC exhibited mild levels of impairment similar to what would be seen in a person whose blood alcohol level was 0.05%.
Four hours later, the THC group of study participants didn’t exhibit any sign of impairment, and their blood tests showed that the cannabinoid had tapered off.
It is interesting to observe that the researchers noticed that, unlike what happens when people take impairment-inducing amounts of alcohol, those who took THC appeared to be aware of their diminished driving abilities as they revealed that they felt less confident while taking to the wheel.
This study is one of the first to provide verifiable data about the impact of small doses of CBD and THC on drivers but shouldn’t be relied upon to indicate what could happen when bigger doses of these compounds are consumed.
Many companies have come up to make a variety of cannabis products, and those companies are thriving. One of the notable firms in this regard is The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER). Its innovative electrolysis process has helped the company establish a strong reputation for its bottled and perfectly balanced alkaline water, as well as its CBD-infused products.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
The Alkaline Water Company (CSE: WTER) (NASDAQ: WTER), a producer of premium bottled alkaline and flavored-infused drinking waters and CBD-infused products, today announced that its president and CEO, Richard Wright, is scheduled to present in two virtual investor conferences during December 2020. According to the update, Wright will participate in various one-on-one meetings with institutional investors during the Roth Virtual Deer Valley Consumer Event on Dec. 10-11, 2020. In addition, Wright will be presenting to a panel of industry experts at 11:20 a.m. Eastern Time on Monday, Dec. 14, 2020, at the LD Micro 13th Annual Main Event. The events will be webcast live (where available), and an updated presentation will be available in the Investor Relations section of The Alkaline Water Company’s website.
To view the full press release, visit http://ibn.fm/edldH
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88 delivers perfect 8.8 pH-balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label: Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88 launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused flavored water is available in six unique all-natural flavors with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp, powder packs, oil tinctures, capsules and gummies. To learn more about the company, visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://ibn.fm/WTER
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- COVID-19, the election, and preference shift towards growth-oriented stocks causing unprecedented stock market volatility
- SRAX’s Sequire SaaS platform unlocks big data investor insights for public companies
- Sequire’s user base grown to over one million investors, traders across 125 companies and partners
- Sequire’s Q3 2020 performance includes over $6.7 million in bookings and 37% increase in subscriptions
The stock market is currently going through a phase of unprecedented volatility caused primarily by political and societal issues, projected to continue well into 2021. As a proactive response, some public companies are choosing to gain clarity about their investor activity through Sequire, a SaaS platform created by SRAX (NASDAQ: SRAX) that unlocks data and insights through warrant tracking, survey creation, events, roadshows and customer relationship/resource management (“CRM”).
According to a recent BTIG report (https://ibn.fm/QXqZ0), issues with COVID-19, the United States presidential election and a general market shift towards growth-oriented stocks are the three major transitory events causing extreme volatility in the markets.
“We’re living through three transitions which, in a period of elevated volatility, are reminders that the path to the long term is a series of short terms — often gut-wrenching, both down and up,” wrote strategists Julian Emanuel and Michael Chu in the BTIG report.
Among other factors connected to the economic downturn, volatile market conditions have added to the toll taken on public companies. Besides poor performance across almost every industry, the situation has been made more challenging by extra pressure from stakeholders on management to keep driving share prices upward.
To that end, Sequire has the potential to add significant value to marketing efforts by unlocking the power of data, engaging current investors and attracting new capital through marketing campaigns. Since its creation in 2019, the platform’s user base has grown rapidly to over one million investors and traders across 125 companies and partners.
Accordingly, Sequire’s performance in Q3 2020 was stellar with over $6.7 million in bookings, its first positive quarter EBITDA, and a 37% increase in subscriptions. SRAX’s overall performance is in line with the success of the platform, with 161% year-over-year and 124% quarter-over-quarter revenue growth.
“As the Sequire platform continues to grow and adapt to customer needs, we are seeing a tremendous increase in our recurring revenue stream,” said SRAX Founder and CEO Chris Miglino. “Sequire is changing the way public issuers interact with and engage their investors, and it shows. We are pleased to report our first quarter of positive EBITDA from our Sequire segment” (https://ibn.fm/buUFN).
SRAX is a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its premier investor intelligence and communications platform. Through Sequire, companies can track investor behaviors and identify trends for use in campaigns to engage current and potential investors across marketing channels.
For more information, visit the company’s website at www.SRAX.com
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights to publicly traded companies through Sequire, today announced that Shaquille O’Neal and Brock Pierce will be the keynote speakers at the 13th Annual LD Micro Main Event, a prominent 2-day virtual investor conference. The event will be held via SRAX’s Sequire Virtual Events platform on Dec. 14 – 15, 2020. Nearly two million active small-cap investors have been invited to the event, which will feature interesting celebrity keynotes and close to 250 presenting companies in a brand new format. Interested parties should visit https://ibn.fm/H8G9W to register and access further details regarding the event.
To view the full press release, visit http://ibn.fm/HpWgB
About SRAX Inc.
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com and MySequire.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Australia hasn’t made a lot of progress towards electrifying its roads. While countries such as the UK, France and Germany have set clear targets for banning the sale of new internal combustion engine (“ICE”) vehicles, Australia’s climate politics has been described by some as “broken.” The country currently has a paltry 20,000 electric vehicles on the road, and only 0.6% of new cars sold in the country are electric.
Now the state of Victoria is planning to introduce a road user tax for electric vehicles (“EVs”) that has the potential to cripple the EV industry before it even takes off. The Victorian government wants to impose a charge of 2.5c a kilometer on electric vehicles and 2c/km on hybrid plug-in cars. The argument is that folk who drive ICE vehicles pay for the roads through a national excise on fuel, a charge EV drivers do not have to pay. According to a government spokesman, the tax will make sure that all Victorian motorists pay their fair share.
However, critics of the proposed tax say that it could jeopardize the adoption of electric vehicles in the country. Federal government modelling, based on current policies, had posited that electric vehicles would make up 65% of new vehicles sold by 2050, says Dr. Lake Whitehead from the University of Queensland’s Dow Center for Sustainable Engineering Innovation. His analysis found that if the 2.5c tax rate were imposed without any incentives, EVs would make only 40% of new vehicle sales by 2050.
This equates to at least 4.9 million fewer electric vehicles sold. As the amount of cars on the roads are forecast to increase significantly, having a reduced number of zero-emission electric vehicles will likely lead to increased greenhouse emissions. Without additional measures such as reducing or altogether removing stamp duty, registration costs and road tolls, Whitehead says, electric vehicles will be too pricey for most drivers to switch.
His analysis found that the 2.5c/km tax would be equivalent to a $4,500 bump in the vehicle’s initial purchase price while a $5 congestion tax usually charged in inner-city areas capped at $15 a day would add $2,800 to the price. He concludes that the proposed EV tax is “completely incongruent” and does not line up with the state’s target of achieving net-zero emissions by 2050. Although a road user tax does make sense, it would only work for the EV industry if it was accompanied by incentives that made EVs more affordable.
Elsewhere, the electric vehicle sector is seeing rapid transformations. For example, Net Element (NASDAQ: NETE), a global fintech firm that supports the making and receiving of electronic payments, is set to merge with EV maker Mullen Technologies Inc.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
- NETE results include year-over-year increases in revenue and transaction volume
- 45% of NETE clients in restaurant business, management expects rebound once states reopen
- NETE plans to divest payments processing model to enter EV industry through reverse-merger with privately-held Mullen Technologies Inc.
Net Element (NASDAQ: NETE), a global financial technology and payments processing company, recently posted its Q3 2020 results showing improved revenues despite continued shutdowns in NY and California. The value-added solutions group supports electronic payments acceptance in an omni-channel environment that spans point-of-sale, e-commerce applications and mobile devices for small to medium enterprises in the U.S. and selected emerging markets.
Business closures due to COVID-19 have affected NETE revenues negatively, particularly for the restaurant industry that comprises approximately 45% of its customer base. With most of the business coming from the southern states, NETE management believes that card processing volumes for the company could rebound sharply if their customers in New York and California could open up again.
Despite the negative outlook and overall sinking economy, company revenues improved in Q3 2020, coming in at $16.7 million from $13.7 million in Q2 2020 (https://ibn.fm/S1d2d). Other highlights from their Q3 results include a year-over-year increase in total transaction volume from $956.2 million to $953.7 million and a year-over-year increase in their North American Transaction Solutions segment to $16.07 million from $15.9 million (https://ibn.fm/od2oj).
The company reported a net loss to common stockholders of approximately $0.52 per share or a total net loss of $2.3 million – almost twice the $1.0 million net loss or $0.24 per share loss for the same period in 2019. The $1.3 million net loss increase is primarily attributed to an increase in non-cash compensation of approximately $1.1 million and an increase in bad debt expense amounting to approximately $200,000.
Gross margin for the quarter was $2.2 million or 13.0% of net revenues, down from $2.7 million or 16.3% for the same period in 2019, attributed to the increased competitive pressure in the industry. Year-over-year operating expenses increased to $4.1 million from $3.6 million while salaries, benefits, taxes and contractor payments decreased by approximately $0.4 million due to staffing reductions connected to COVID-19.
Earlier this year, NETE announced plans to divest itself of its payments processing services in order to enter the electric vehicle industry through a reverse merger with Mullen Technologies. Following the requisite approvals, the transaction will allow the stakeholders of privately-held Mullen to gain a majority of the new stock while accelerating the process of taking the new company public. NETE continues to work diligently on the transaction while Mullen completes its audit and S-4 document with expectations to have it filed by the end of the year.
“We continue working diligently in an effort to finalize the Mullen merger for the benefit of our shareholders,” said Net Element Executive Chairman Oleg Firer.
Formerly ranked as one of North America’s fastest growing companies on Deloitte’s Technology Fast 500(TM) in 2017 and 2018, NETE offers 100-plus payment solutions in an omni-channel environment for small to medium enterprises. Following the approval of its reverse merger with California-based Mullen Technologies, the company plans to divest its payments-as-a-service business model and enter the electric vehicle industry.
For more information, visit the company’s website at www.NetElement.com.
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
The multibillion-dollar natural resources industry in Utah is thriving, with copper being the most valuable metal extracted in the industry. The Utah Geological Survey (UGS) recently released a report on the state’s mining activities in the last year. Last year’s figures indicate a growth of 2.4%, which equates to more than $90 million. The most valuable metal mineral of the state is copper while the total value with regard to extractive resources, inclusive of gas and oil, is approximated at $6.5 billion. Mining takes up a huge chunk of this value — 60% of it — bringing the value of minerals mined to $3.9 billion.
Michael Vanden Berg, a senior scientist at UGS, stated that the natural resource industry was a strong contributor to the state’s economy in terms of tax revenue and supplying the materials required to develop and support the society. The industry, he noted, also creates jobs for many individuals, especially in rural communities.
The aforementioned report sums up the 2019 values and mineral resource output data for Utah’s mining industry. The report includes unconventional fuel and industrial minerals data as well as data on nonfuel mineral resources, counting precious and base metals, uranium and coal. The report also offers updates on various exploration projects.
In the report, readers learn that Utah was among the top states in the production of industrial minerals and metals last year. Under industrial mineral products, brine was found to be the most valuable, accounting for $483 million with regard to the state’s mining value. Utah’s most precious metal — copper — was valued at $1.2 billion. Comprehensively, metals made up $2.1 billion of the state’s mining value with industrial minerals making up $1.3 billion. In addition to this, the coal market brought in $480 million.
The state is still the only beryllium generator in the country. Its total output of 2019 made up roughly 65% of the total beryllium produced globally. Beryllium is a tough and light metal that has various applications in telecommunications, computer, medical, automobile, aerospace and defense.
Last year, extractive industries in Utah, inclusive of gas and oil, paid federal mineral lease disbursements of roughly $80 million. The coal, gravel and sand, industrial mineral, and metal mining industries in the state also paid property taxes of more than $82 million. Severance taxes related to mining of about $13 million were also paid for by the industry.
Mining employment was cited as stable with employment at coal mines growing from 1,185 workers to 1,397 workers as of 2019.
Outside Utah, the U.S. mining sector has many success stories for the world. A case in point is Energy Fuels Inc. (TSX: EFR) (NYSE American: UUUU), a Colorado-based firm that has surpassed all others across the country with regard to the production of two critical minerals: uranium and vanadium.
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
President Vladimir Putin of Russia has ordered that health officials in the country begin coronavirus vaccinations next week. The country has manufactured about 2 million doses of its vaccine.
President Putin’s statement was made on the same day that Britain gave its seal of approval for the BioNTech-Pfizer vaccine to be made available to the public, also starting next week. In the previous week, the country produced provisional test results of the Sputnik V vaccine that showed that it was more than 95% effective. The vaccine was developed by the National Research Center for Epidemiology and Microbiology.
The vaccine is currently in the phase 3 clinical trial. This is the final stage of testing and has involved around 40,000 volunteers. The vaccine was named after a satellite from the Soviet era. Putin urged health officials to arrange for widespread vaccinations that would ensure that by the end of the coming week, the country would have already begun extensive vaccination. He added that medics and teachers would be the first to be vaccinated, with an additional 2 million vaccine doses or more being manufactured in the days to come.
The Sputnik V vaccine is given in two doses, with the second dose being administered after 21 days. The jab uses two human adenovirus vectors and will be administered voluntarily to individuals. Additionally, the jab will be free for all citizens of the country.
The defense ministry of Russia had previously announced that a widespread campaign to vaccinate service personnel in the army had begun. The objective is to vaccinate more than 400,000 military personnel, aiming to have inoculated at least 80,000 soldiers by the end of 2020.
Mikhail Murashko, Minister of Health in Russia, stated during a UN video link that more than 100,000 individuals had already been inoculated with the Sputnik V vaccine. The video link was centered on vaccine presentation. The head of the Russian Direct Investment Fund, Kirill Dmitriyev, who was involved in vaccine development, spoke at the same conference, stating that above 40 nations had expressed interest in the Sputnik V vaccine. In addition to this, he said, orders totaling more than 1.2 billion vaccine doses had been made.
Currently, Russia has among the highest cases of the coronavirus globally, with 41,053 casualties and 2,347,401 cases. Last week, health officials reported 25,345 new cases and 589 fatalities. To help contain the virus, authorities plan to close restaurants, concert halls, theatres, museums and bars in St. Petersburg starting Dec. 31.
The novel coronavirus isn’t the only health challenge for which biomedical companies have been working to find solutions. Other challenges, such as chronic diseases, have also received their fair share of attention. For instance, Israel- and New York-based DarioHealth Corp. (NASDAQ: DRIO) has been helping chronic disease patients to make beneficial lifestyle changes using DarioHealth’s smartphone-based software.
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Loop Insights (TSXV: MTRX) (OTCQB: RACMF), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement and automated venue tracing to the brick-and-mortar space, today announced approval by its board of directors to begin the process of uplisting to major North American stock exchanges. According to the update, Loop plans to apply to have its common shares uplisted to the Toronto Stock Exchange (“TSX”), as a technology company, from the TSX Venture Exchange (“TSXV”), subject to meeting certain conditions and the approval of the TSX. Additionally, if successful in uplisting to the TSX, Loop intends to, as soon as practical, begin the process of filing a Form F-1 Registration Statement with the Securities and Exchange Commission of the United States (the “SEC”), which will enable Loop to apply to be listed on the NASDAQ. “As a result of our immutable relevancy, high demand for Loop’s products, pipeline growth, and ability to easily scale into a global marketplace that is in full press digital transformation, we expect a continued accelerated pace that now warrants an uplist and dual list strategy that will attract institutional investors commensurate with our anticipated profile in 2021 and far beyond,” said Loop Insights CEO Rob Anson.
To view the full press release, visit http://ibn.fm/nkt1Q
About Loop Insights Inc.
Loop Insights is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, contact tracing and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network. For more information, visit the company’s website at www.LoopInsights.ai.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
